Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences (TSX:PMN) moves closer to Nasdaq listing

John Ballem  June 22, 2022

ProMIS Neurosciences Announces Debt Amendment and Conversion

GlobeNewswire June 22, 2022

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

GlobeNewswire June 22, 2022

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

GlobeNewswire June 22, 2022

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

GlobeNewswire May 17, 2022

CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

GlobeNewswire May 13, 2022

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

GlobeNewswire May 13, 2022

ProMIS Neurosciences Announces First Quarter 2022 Results

GlobeNewswire May 13, 2022

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

GlobeNewswire May 3, 2022

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

GlobeNewswire April 28, 2022

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

GlobeNewswire April 19, 2022

Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)

PR Newswire April 18, 2022

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

GlobeNewswire April 7, 2022

ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

GlobeNewswire April 7, 2022

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

GlobeNewswire March 24, 2022

ProMIS Neurosciences (TSX:PMN) shares experimental Alzheimer's vaccine results

Caroline Egan  March 22, 2022

ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

GlobeNewswire March 22, 2022

ProMIS Neurosciences Announces Fiscal Year 2021 Results

GlobeNewswire March 17, 2022

ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) and Related Neurological Disorders

GlobeNewswire March 10, 2022

ProMIS Neurosciences' (TSX:PMN) PMN310 antibody demonstrates significant cognitive benefits

Brieanna McCutcheon  March 2, 2022